Cegedim Strategic Data's Real-World Evidence Shows That Diabetes Management Varies Among the Top 5 European Countries PARIS--(Marketwired - Jun 5, 2013) - Cegedim Strategic Data (CSD), leading provider of healthcare market research, has published the results of its study on Type 2 diabetes patients being treated with OADs (Oral antidiabetic drugs) or GLP-1 (Glucagon-like peptide agonists) treatments in France, Spain, Germany, Italy and the UK.
June 5, 2013 - Marketwire